Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Certain infectious agents are recognised causes of cancer and other chronic diseases. To understand the pathological mechanisms underlying such relationships, we designed a Multiplex Serology platform to measure quantitative antibody responses against 45 antigens from 20 infectious agents.

Some infectious agents are recognised causes of cancer and other chronic diseases. In humans, well-known examples of such causal agents include human papillomaviruses that cause cervical cancer,  and Epstein-Barr virus inked to Burkitt's lymphoma. More recently, studies from longitudinal cohorts, where participants are followed over an extended period, have shown a link between EBV infection and the development of Multiple sclerosis. 

While there is growing evidence that infectious agents may contribute to a wider range of cancers and chronic diseases than currently recognised in the medical literature, the associations, and mechanisms behind these, are much less clear.  

In our recent paper in Nature Communications, we present the development and validation of a Multiplex Serology platform to measure quantitative antibody responses against 45 antigens from 20 infectious agents including human herpes, hepatitis, polyoma, papilloma (HPV), and retroviruses, as well as Chlamydia trachomatisHelicobacter pylori and Toxoplasma gondii. These agents were selected after wide consultation with infectious disease and public health clinicians and epidemiologists, to represent infections that were most likely to be relevant to chronic diseases in world-wide populations (but particularly the UK), and which could be readily detected using antibodies. We used the antibody assay because it is familiar to researchers and clinicians working in the fields of infectious disease and epidemiology, and it is robust and reproducible and amenable to high-throughput analyses. To demonstrate the utility of this panel as a high-throughput alternative for single-agent cross-sectional epidemiological studies and illustrate potential for further investigating both well-recognised and potentially novel host-pathogen-environment-disease associations, we applied this to a subset of 9695 randomly selected participants from UK Biobank. 

Read the full story on the Nature Communications website.

Read the full paper: "Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank" on the Nature communications website.

 

 

Similar stories

Oxford expands the Cartography collaboration with Janssen

The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation

Outbreak: fighting coronavirus

In a new Oxford Science Blog, Charvy Narain (Communications & Public Engagement Manager, Radcliffe Department of Medicine) talks to some of the Oxford University researchers coming together to fight the novel Coronavirus outbreak.

Researchers find new cells that repair tissue

Researchers from Nuffield Department of Medicine have discovered that a newly discovered group of cells can help repair tissues in the body.

Rapidly spreading multidrug-resistant parasites render frontline malaria drug ineffective in southeast Asia

A rapidly evolving multi-drug resistant lineage of P. falciparum malaria parasites continues to spread in South East Asia, leading to alarmingly high treatment failure rates in Cambodia, Thailand and Vietnam for DHA-piperaquine, one of the world’s most important anti-malaria drugs.

New study shows faster way to cure vivax malaria

A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.

Award-winning citizen science project tackling TB gets millionth classification

An award-winning Oxford-based international project to tackle antibiotic resistance has achieved its one millionth classification.